Hit-to-Lead Archives - WuXi Biology

Innovative Technologies in Early Drug Discovery

In this webinar, WuXi AppTec scientists discuss the latest innovative technologies and products in early-stage drug discovery. Viewers will gain...

Advanced On-bead DEL Technology for Enhanced Drug Discovery Screening

DNA-encoded library (DEL) technology has been recognized as a major screening method with unique advantages for offering vast chemical diversity...

Discovery of a Novel Covalent Inhibitor Using DEL

With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets. Covalent drugs...

Discovery of GuaB Inhibitors for the Treatment of Tuberculosis

Tuberculosis is the leading cause of death from an infectious disease and is caused by Mycobacterium tuberculosis (MTB). Inosine-5′-monophosphate dehydrogenase...

Small Molecule Reactivator of p53 Y220C Mutant

Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...

Discovery Platform for Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

In Silico Drug Discovery Platform

WuXi AppTec offers a comprehensive platform of in silico drug discovery services to accelerate the process of hit finding and...

Integrated Screening in Hit Identification

Despite the availability of modern screening technologies, identification and optimization of hits against poorly druggable targets remains a significant challenge...

Addition of Covalent Warhead and DEL-Generated Hit Fragmentation Empower FBDD

Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds. At the...

Knowledge Library